Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06405256 Recruiting - Brain Metastases Clinical Trials

Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain Metastases

Start date: January 3, 2020
Phase:
Study type: Observational [Patient Registry]

This study is an ambispective cohort study to evaluate the displacement and deformation of large brain metastases (BM) treated with magnetic resonance imaging-guided adaptive radiotherapy (MRIgART)

NCT ID: NCT06405009 Recruiting - Gastric Cancer Clinical Trials

Prediction Model of Occult Omental Metastasis in Patients With Gastric Cancer

Start date: April 22, 2024
Phase:
Study type: Observational

A complete omentectomy is typically recommended during radical total gastrectomy for gastric cancer, though its impact on survival remains unclear. This study aimed to assess the frequency and risk factors of metastases in the greater omentum in gastric cancer patients undergoing gastrectomy. It will involve a single prospective cohort of consecutive patients who underwent total gastrectomy with complete en bloc omentectomy and modified D2 lymphadenectomy. Post-surgery, the omentum will dissect from the gastrectomy specimen beyond the gastroepiploic vessels and examine separately for pathological assessment. The primary outcome will focus on the detection of omental metastases.

NCT ID: NCT06399926 Recruiting - Lung Cancer Clinical Trials

Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir

Start date: October 30, 2023
Phase:
Study type: Observational

This is a open-label, multi-center prospective observation study for the efficacy and safety of intraventricle pemetrexed disodium via ommaya reservoir in the treatment of leptomeningeal metastasis with lung cancer who have failed at least one targeted therapy. In detail: At least the treatment failure was after third-generation EGFR-TKIs in EGFR-mutated lung cancer; or at least the treatment failure was after second-generation ALK-TKIs in ALK-mutated lung cancer; or at least the treatment failure was after one-line of targeted-TKIs in ROS1-mutated non-squamous non-small lung cancer.

NCT ID: NCT06392217 Recruiting - Breast Cancer Clinical Trials

clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases

Start date: March 12, 2024
Phase:
Study type: Observational

This is a real-world study to explore the efficacy and safety of incadronate in the treatment of breast cancer patients with bone metastases.

NCT ID: NCT06389123 Recruiting - Metastatic Cancer Clinical Trials

Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas

Start date: April 1, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase I study to evaluate the safety and efficacy of the [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer.

NCT ID: NCT06383780 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Start date: May 1, 2024
Phase: Phase 3
Study type: Interventional

This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP(Gemcitabine combined with cisplatin) regimen in combination with Tislelizumab versus the TPC(cisplatin, nab-paclitaxel and capecitabine)regimen in combination with Tislelizumab for the first-line treatment of Nasopharyngeal Carcinoma patients With Bone Metastasis.

NCT ID: NCT06381648 Recruiting - Cholangiocarcinoma Clinical Trials

Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)

LyMIC
Start date: April 15, 2023
Phase:
Study type: Observational

Lymph node metastasis (LNM) is a major prognostic factor in intrahepatic cholangiocarcinoma (ICC), and accurate preoperative prediction of the presence or absence of LNM has significant clinical implications in determining treatment strategy. Despite this, there are currently no reliable biomarkers established to detect LNM in ICC. This study seeks to develop a liquid biopsy assay that can accurately detect LNM before treatment in ICC patients.

NCT ID: NCT06376292 Recruiting - Clinical trials for Solid Tumor Leptomeningeal Metastasis

A Prospective Study of Whole-Brain RT Combined With Thiotepa Sheath Injection Combined With Systemic Therapy for the Primary Disease in the Treatment of Meningeal Metastases in Solid Tumors

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this prospective, single-arm exploratory clinical study is to explore the safty and efficacy of whole-brain radiotherapy combined with Thiotepa sheath injection combined With Systemic Therapy for the Primary Disease in the Treatment of Meningeal Metastases in Solid Tumors How works well was the combined therapy? How safe was combined therapy? Participants will receive whole brain radiotherapy combined with intrathecal injection of Thiotepa twice a week for a total of 4 weeks. Evaluate the efficacy and safety every 2 cycles. Researchers will evaluate whether this combination treatment is safe and whether it is more effective than previous studies.

NCT ID: NCT06372145 Recruiting - Clinical trials for Relapsing Multiple Sclerosis

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Start date: April 16, 2024
Phase: Phase 3
Study type: Interventional

This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b LTS (LTS16004) or 1 of the 4 Phase 3 tolebrutinib pivotal trials (GEMINI 1 [EFC16033], GEMINI 2 [EFC16034], HERCULES [EFC16645], or PERSEUS [EFC16035]). SUBSTUDY: ToleDYNAMIC substudy

NCT ID: NCT06367491 Recruiting - Bone Metastases Clinical Trials

National Database of Bone Metastases

BDMO
Start date: October 8, 2013
Phase:
Study type: Observational [Patient Registry]

BDMO is an Italian multicentre, observational, prospective study that collects data from all patients with bone metastases referred to each participating centre, using an on-line software 'tailor-made' for data collection.